2025-2034 Biologics Outsourcing Market Roadmap: Insights for Competitive Advantage

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Biologics Outsourcing Market Size By 2025?
In recent times, the biologics outsourcing market has witnessed swift expansion. Predictions indicate an increase from $20.06 billion in 2024 to $22.7 billion in 2025, marking a compound annual growth rate (CAGR) of 13.2%. Factors contributing to the preceding term's growth include escalating R&D expenditures, regulatory pressures, the necessity for specialized knowledge, and globalization.

How Big Is the Biologics Outsourcing Market Size Expected to Grow by 2029?
The market for biologics outsourcing is anticipated to experience substantial expansion in the coming years, reaching a valuation of $37.52 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. Factors contributing to the predicted growth during this period include the proliferation of emerging markets, the rise of personalized medicine, strategic partnerships, and the expiration of biological drug patents. Significant trends set to impact this period include technological advancements, increased complexities in outsourcing, growth in the biosimilars market, the incorporation of data analytics, and a robust supply chain.

View the full report here:
https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

Which Key Market Drivers Powering Biologics Outsourcing Market Expansion and Growth?
The biologics outsourcing market's growth is predicted to be driven by an increase in cancer instances. Cancer is a collection of diseases that can form in almost any organ or tissue when abnormal cells multiply without control, overstep their normal boundaries, and spread to other organs or invade nearby body parts. In battling cancer, biologics outsourcing plays a pivotal role by offering special expertise, resources, and establishment for the creation, manufacture, and clinical supply of biologic treatments such as monoclonal antibodies, immunotherapies, and other targeted biologics. These are employed for the detection, treatment, and control of various cancer forms. For example, the National Center for Biotechnology Information, a U.S. intergovernmental organization, recorded 1,958,310 new cancer cases in the U.S. in January 2023 and projected 609,820 cancer deaths in 2023. Moreover, the annual number of new cancer cases is anticipated to reach 29.5 million and cancer-related fatalities to hit 16.4 million by 2040. Hence, the escalating number of cancer instances is fuelling the expansion of the biologics outsourcing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12573&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Biologics Outsourcing Market?
The rise in advancements in the field of biologics is a trend that has captured a lot of attention in the biologics outsourcing market. To maintain their place in the market, big players in the industry are adapting to new technological advancements. One good example would be from the month of February 2022, when Abzena, which is a US-based contract development and manufacturing organization, Alira Health - another U.S. healthcare firm, and Oncodesign - a France-based biopharmaceutical company, initiated DRIVE-Biologics. This consortium is specially made for biological drug finding and advancement programs. What it does is, it offers integrated solutions bundled with special services ranging from the discovery of biology to manufacturing commercially and clinically. This alliance, which merges industry leadership in areas like design and developability, proof of concept in preclinical pharmacology and pharmaco-imaging, toxicology, and designing clinically through to commercial manufacturing, is aimed at simplifying information exchange and providing deliverables for programs to help reduce the risks associated with biologics development. Furthermore, the partners will be able to draw on expertise during all stages of drug discovery and development, which include design, preclinical, clinical, and CMC (chemistry, manufacturing, and control).

What Are the Emerging Segments in the Biologics Outsourcing Market?
The biologics outsourcing market covered in this report is segmented -

1) By Product Type: Antibodies, Recombinant, Vaccines, Protein, Other Products
2) By Source: Human, Microbial, Other Source
3) By Application: Oncology, Cellular And Gene Therapy, Blood And Blood-Related Products Development, Vaccine Development, Stem Cell Research, Other Applications
4) By End User: Pharmaceutical Industries, Biotechnology Industries, Contract Development And Manufacturing Organization(CDMO)

Subsegments:
1) By Antibodies: Monoclonal Antibodies, Polyclonal Antibodies
2) By Recombinant: Recombinant Proteins, Recombinant DNA Products
3) By Vaccines: Therapeutic Vaccines, Preventive Vaccines
4) By Protein: Enzymes, Hormones, Cytokines
5) By Other Products: Gene Therapies, Cell Therapies, Biosimilars

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12573&type=smp

Who Are the Global Leaders in the Biologics Outsourcing Market?
Major companies operating in the biologics outsourcing market include AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Lonza Group Ag, Catalent Inc., Sartorius Stedim Biotech S.A., Charles River Laboratories International Inc., WuXi Biologics Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., CordenPharma GmbH, Ajinomoto Bio-Pharma Services, Syngene International Limited, Rentschler Biopharma SE, Albany Molecular Research Inc., KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies Inc., Avid Bioservices Inc., BioVectra Inc., ProBioGen AG, ABL Inc., Vibalogics GmbH, JHL Biotech Inc., Goodwin Biotechnology Inc., Crown Bioscience Inc., Cytovance Biologics Inc., LakePharma Inc., AGC Biologics GmbH, Biomay AG, Polpharma Biologics S.A.

Which are the Top Profitable Regional Markets for the Biologics Outsourcing Industry?
North America was the largest region in the biologics outsourcing market in 2024. The regions covered in the biologics outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12573

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.